SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around the crypto, touting its cultural significance and potential for growth within the cannabis space. Despite limited availability on major exchanges, supporters are actively sharing links to its website and DEX screener, emphasizing its connection to cannabis culture. Community members express bullish sentiment and encourage others to accumulate.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as discussions swirl around a potential equity stake from the Trump administration to secure U.S. rare earth mineral supply, specifically regarding the Greenland mine. The community is analyzing the implications of this deal, drawing comparisons to similar situations and anticipating significant upward movement. Many are expressing bullish sentiment, viewing CRML as a strategic play amid growing geopolitical interest in critical minerals.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the stock experiences upward momentum, leading to community excitement about potential gains. Discussions revolve around the possibility of government funding and the significance of upcoming milestones like NOAA approval, which some believe could trigger a significant price increase. There is also increasing bullish sentiment around the company's overall prospects in deep-sea mining.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is trending amid discussions around technical levels, potential Prime Day impact, and analyst ratings, with community sentiment split between bullish expectations and frustration over recent price action. Some traders are pointing to Goldman Sachs' upgraded price target, while others are wary of AWS market share and potential risks, highlighting a divergence in perspectives. Concerns are emerging around the stock's YTD performance compared to other tech giants.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending with significant trading volume as investors discuss potential catalysts, including upcoming airshows and speculation around partnerships (especially with Tesla). Community sentiment is bullish, with many anticipating a breakout and expressing long-term confidence. Some traders cite the high short interest as a potential for a squeeze, while others focus on the company's progress towards certification and commercialization of its eVTOL technology.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as analysts raise price targets, citing strong earnings growth and AI leadership, though some caution against overvaluation in the AI sector. Community discussions also focus on the Xbox Game Pass price increase and its potential impact. Investors are weighing the company's AI investments against concerns of a broader tech bubble.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a report highlighting security flaws in its battlefield communications tech, though the company claims the report is outdated and inaccurate, sparking debate within the community. Some investors view the dip as a buying opportunity, citing Palantir's strong fundamentals and potential for recovery, while others express concern about the stock's valuation and potential for further decline. Discussions also involve the broader context of AI stocks and Palantir's position within the defense sector.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics (RR) is trending as the community discusses its recent strength and potential catalysts, including an upcoming conference and possible Nvidia partnership. Bullish sentiment is fueled by insider buying, while some express concerns about the company's financials and potential dilution. The stock's parabolic wedge pattern and potential breakout are also key talking points.

CATULU | THE THREADED FAMILIAR  Catulu is like Tamagotchi for the Twitter age — except your pet lives on the timeline, and the more you play, the more everyone sees it.  Platform & Core Mechanics Platform: Twitter + Web3 (Solana) Core Loop: Tweeting = Feeding, Cleansing, Training Tokens: $CATULU (native currency of the ecosystem)   Level up your characters to unlock more avatar images , get into top ranks on leaderboard and earn LP rewards.

CATULU

CATULU is trending as social media buzz highlights bullish sentiment and potential for a rapid price increase. Community members are discussing the token's 'cat meme' potential and encouraging others to buy in quickly, citing an active live chat and 'heating up' charts. The token appears to be associated with the Solana blockchain.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401jK is trending as community members rally around its meme-driven narrative of disrupting traditional retirement plans. Fueling the conversation is the coin's strong community and recent price consolidation, with many anticipating a significant breakout soon. Some are drawn to 401jK's vision of simplified retirement, contrasting it with the perceived failures of conventional 401(k) systems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Artelo Biosciences, Inc. (ARTL) surged 57% on Monday afternoon after the company announced positive preclinical data highlighting the potential of its drug candidate in treating depression and anxiety.The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with leading antidepressant medication, Sertraline (Zoloft).ART12.11 <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.artelobio.com/news-events/press-releases/detail/153/artelo-biosciences-announces-positive-preclinical-efficacy">improved</a> sucrose preference and social motivation, which are established behavioral markers of depressive-like states, to near-baseline levels.However, unlike Sertraline, ART12.11 reversed stress-induced deficits in both spatial and short-term memory without negatively impacting social memory, the company added.<a href="https://stocktwits.com/symbol/ARTL">Artelo</a> added that the findings demonstrate the candidate’s potential as a candidate for treating depression and anxiety, especially in patients where cognitive dysfunction occurs, which is a known limitation of existing selective serotonin reuptake inhibitor therapies like Sertraline.ART12.11 is Artelo’s wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP).Prior preclinical research studies in animals with ART12.11 demonstrated greater behavioral and pharmacokinetic results compared to Cannabidiol or Epidiolex.Artelo CEO Gregory D Gorgas said that although strong antidepressant effects were noted with ART12.11 in prior studies, the company is “especially encouraged” by these new comparative findings.On Stocktwits, retail sentiment around Artelo, however, fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_12_27_08_PM_png_b2e63d4064.webp" alt="ARTL's Sentiment Meter and Message Volume as of 12:27 p.m. ET on July 7, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>ARTL's Sentiment Meter and Message Volume as of 12:27 p.m. ET on July 7, 2025 | Source: Stocktwits</figcaption></figure>ARTL stock is up by about 148% this year and by about 99% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/retail-buying-hit-3-4-trillion-in-the-first-half-of-2025-yet-market-chatter-has-faded/chFtYldR5fx">Retail Buying Hit $3.4 Trillion In The First Half Of 2025, Yet Market Chatter Has Faded</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression Drug

The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with the leading antidepressant medication, Sertraline (Zoloft). 

Equity

The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with the leading antidepressant medication, Sertraline (Zoloft). 


Shares of Artelo Biosciences, Inc. (ARTL) more than doubled on Monday after the company announced favorable results from its first in-human study evaluating ART26.12, a non-opioid treatment candidate for persistent pain.ART26.12 is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is nerve damage caused by certain chemotherapy drugs, leading to sensory, motor, or autonomic dysfunction.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/30/3107392/0/en/Artelo-Biosciences-Announces-Positive-First-in-Human-Data-for-ART26-12-a-Novel-Non-Opioid-Treatment-Candidate-for-Persistent-Pain.html">said</a> that all adverse events identified during the in-human trial were mild, transient, and self-resolving. Furthermore, the study demonstrated predictable pharmacokinetics for the drug.Pharmacokinetics is defined as the quantitative analysis of the processes of drug absorption, distribution, and elimination that determine the time course of drug action in response to an administered drug dose.The company said that complete dose-exposure profiles were explored, and tests confirmed dose-dependent, linear absorption across the evaluated range.Andrew Yates, Chief Scientific Officer at Artelo, said that the company is “particularly pleased” that the safety and pharmacokinetic profile generated from ART26.12’s non-clinical studies translated well to the human experience.According to Artelo, the chronic pain therapeutics market exceeded $97 billion globally in 2023 and is expected to surpass $159 billion by 2030, driven by the increasing prevalence of conditions such as neuropathic pain, arthritis, and fibromyalgia.The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.On Stocktwits, retail sentiment around ARTL jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_30_at_1_46_11_PM_png_54bfa7b48c.webp" alt="ARTL's Sentiment Meter and Message Volume as of 1:45 p.m. ET on June 30, 2025 | Source: Stocktwits" width="624" height="62"><figcaption>ARTL's Sentiment Meter and Message Volume as of 1:45 p.m. ET on June 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, flagged that the company will need cash to progress its pipeline, and hence, dilution is likely.<stembedurl>https://stocktwits.com/ElPutoToro/message/619463192</stembedurl>The company had cash and investments totaling only $0.7 million as of the end of the first quarter.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up by about 135% this year and by about 85% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-q2-deliveries-expected-to-fall-below-consensus-jpmorgan-underscores-sizable-shortfall/chmZF6zRR7Q">Tesla Q2 Deliveries Expected To Fall Below Consensus, JPMorgan Underscores A ‘Sizable’ Shortfall</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artelo Biosciences Stock Doubles After Positive Results In First Non-Opioid Pain Treatment Trial

Shares of Artelo Biosciences, Inc. (ARTL) more than doubled on Monday after the company announced favorable results from its first in-human study evaluating ART26.12, a non-opioid treatment candidate for persistent pain.

The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.


Brokers Offer Predictions for Artelo Biosciences, Inc.'s FY2024 Earnings (NASDAQ:ARTL)

Artelo Biosciences, Inc. (NASDAQ:ARTL - Free Report) - Research analysts at HC Wainwright decreased their FY2024 EPS estimates for shares of Artelo Biosciences in a research note issued on...

Artelo Biosciences, Inc. to Post Q1 2024 Earnings of ($1.05) Per Share, HC Wainwright Forecasts (NASDAQ:ARTL)

Artelo Biosciences, Inc. (NASDAQ:ARTL - Free Report) - Equities researchers at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Artelo Biosciences in a report released on...

Artelo Biosciences reports 2023 EPS ($3.14), consensus ($2.56)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Major achievements in 2023 lay the foundation for key upcoming milestonesSOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage...

Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Up 117.6% in February

Artelo Biosciences, Inc. (NASDAQ:ARTL  Get Free Report) was the target of a large growth in short interest in the month of February. As of February 29th, there was short interest totalling...

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & JohnsonSOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc...

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

SOLANA BEACH, CA / ACCESSWIRE / February 15, 2024 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

Artelo Biosciences Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

ARTL
Artelo Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ARTL News

ARTL Artelo Biosciences Inc